A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study

[1]  O. Pedersen,et al.  Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study , 2018, Diabetologia.

[2]  9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[3]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[4]  Björn Eliasson,et al.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.

[5]  O. Pedersen,et al.  Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. , 2017, Kidney international.

[6]  Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019 , 2018 .

[7]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[8]  O. Pedersen,et al.  Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.

[9]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[10]  J. Shaw,et al.  Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes , 2016, Diabetologia.

[11]  P. B. Jensen,et al.  Societal costs of diabetes mellitus in Denmark , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[12]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[13]  P. Jhund,et al.  Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.

[14]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[15]  J. Tuomilehto,et al.  Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults , 2013, European Journal of Epidemiology.

[16]  Bernard C. K. Choi,et al.  Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada , 2012, Population Health Metrics.

[17]  W. Lu,et al.  Increasing Prevalence of Type 2 Diabetes in Chinese Adults in Shanghai , 2012, Diabetes Care.

[18]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[19]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[20]  Elsebeth Lynge,et al.  The Danish National Patient Register , 2011, Scandinavian journal of public health.

[21]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[22]  O. Pedersen,et al.  Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes , 2008, Diabetes Care.

[23]  M. Pladevall,et al.  The impact of diabetes on employment and work productivity. , 2005, Diabetes care.

[24]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[25]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.